Project Grant R01EY036396
Award Date
9/1/24
Completion Date
6/30/29
Dollars Obligated
$447K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This $526,841 Project Grant award, provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), aims to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The principal investigator at Vanderbilt University Medical Center will conduct research to determine how disruptions in cGMP signaling pathways impact retinal astrocyte and vascular networks, leading to retinal ganglion cell (RGC) metabolic stress and axon degeneration in glaucoma. The...
This federal Project Grant award of $362,415 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of the orexin neurotransmitter system in regulating intraocular pressure (IOP) and its potential implications for glaucoma treatment. The research aims to: 1) examine the influence of the brainstem raphe pallidus on IOP elevations induced by stimulation of the dorsomedial hypothalamus/perifornical region, 2) assess the...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This $568,122 Project Grant from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research at Baylor College of Medicine to unequivocally confirm the contribution of neurovascular dysfunction to glaucoma pathogenesis and identify endothelial cell-specific ligands with potential for neuroprotective therapy. The research aims to globally map all ligands binding to ocular hypertension and healthy retinal cells, quantify their binding activities, and...
The National Eye Institute (NEI) awarded a $679,159 Project Grant (CFDA 93.867 - Vision Research) to The Schepens Eye Research Institute, Inc. to investigate the combined effects of aging and elevated intraocular pressure (IOP) on the development of glaucoma and the retinal ganglion cell (RGC) transcriptome. The research aims to: 1) Demonstrate that elevated IOP-induced glaucoma is more severe in aging mice and that transient AAV2-OSK (Oct4, Sox2, Klf4) mediated epigenetic reprogramming can...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), is providing $481,250 to Vanderbilt University Medical Center to investigate the role of the ADAMTS10 gene in the development of glaucoma. The grant aims to define the mechanism by which ADAMTS10 promotes transforming growth factor beta (TGF-β) signaling, and test the hypothesis that reduced TGF-β signaling resulting from glaucoma-causing ADAMTS10 mutations leads to...
The National Eye Institute (NEI) awarded a $234,000 Project Grant (CFDA 93.867 - Vision Research) to Oregon Health & Science University (OHSU) to enhance stem cell restoration of intraocular pressure (IOP) homeostasis using senolytic treatments for glaucoma. The project aims to explore the use of senotherapeutics, including senolytics and senoreverters, to restore IOP homeostatic function in glaucomatous tissue, with or without the assistance of stem cell transplantation. This research has...
This $218,068 Project Grant awarded by the National Eye Institute (NEI) under CFDA Program 93.867 "Vision Research" aims to structurally and biochemically characterize wild-type lysyl oxidase-like 1 (LOXL1) protein and variants associated with pseudoexfoliation glaucoma (XFG). The project will examine how specific LOXL1 variants impact the protein's structure, processing, interactions, and catalytic activity to further understanding of how LOXL1 contributes to XFG, the most common form...